Oncotarget

Meta-Analysis:

Efficacy and safety of pancreatic enzyme replacement therapy on exocrine pancreatic insufficiency: a meta-analysis

Can Gan, Yan-Hua Chen, Ling Liu, Jin-Hang Gao, Huan Tong, Cheng-Wei Tang _ and Rui Liu

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:94920-94931. https://doi.org/10.18632/oncotarget.21659

Metrics: PDF 2419 views  |   HTML 4550 views  |   ?  


Abstract

Can Gan1,2,*, Yan-Hua Chen1,2,*, Ling Liu1,2, Jin-Hang Gao1, Huan Tong1,2, Cheng-Wei Tang1,2 and Rui Liu1

1Division of Peptides Related with Human Diseases, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China

2Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China

*These authors contributed equally to this work and should be considered as co-first authors

Correspondence to:

Cheng-Wei Tang, email: [email protected]

Rui Liu, email: [email protected]

Keywords: pancreatic enzyme replacement therapy, exocrine pancreatic insufficiency, efficacy, safety, standardization

Received: July 12, 2017     Accepted: September 21, 2017     Published: October 07, 2017

ABSTRACT

Background: Pancreatic enzyme replacement therapy (PERT) is widely applied to patients with exocrine pancreatic insufficiency (EPI), but its effect and safety has not been quantified. Therefore we performed a meta-analysis to determine the efficacy and tolerance of PERT on patients with EPI.

Materials and Methods: PubMed, Medline, Cochrane library database, Evidence-based medicine/clinical trials published before December 2016 were searched by two independent reviewers to identify prospective randomized controlled trials (RCTs).

Results: Seven RCTs, randomizing a total of 282 patients, were filtrated and assessed qualitatively (Jadad score). PERT increased CFA (WMD: 26.56, 20.35 to 32.76, I2 = 79.6%, P < 0.001) compared with baseline, and CFA (WMD: 17.97, 12.61 to 23.34, I2 = 76.7%, P < 0.001) vs. placebo. Meanwhile, CNA, SFE, SNE and SW were significantly improved in PERT compared with baseline and placebo, with no statistical differences in adverse events. Subgroup analysis indicated that standard forms of PERT displayed more effectiveness with significantly decreased heterogeneity, and large sample size also reduced the heterogeneity to some degree.

Conclusions: PERT is demonstrated to be effective and tolerable in patients with EPI, especially using standard administration of PERT. Larger and higher quality studies on EPI are demanded to long-term effect of standard PERT treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21659